Piramal Pharma (PPLPHARMA) Panoramica del titolo
Piramal Pharma Limited opera come azienda farmaceutica in Nord America, Europa, Giappone, India e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 0/6 |
PPLPHARMA Community Fair Values
Create NarrativeSee what 16 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Piramal Pharma Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | ₹213.67 |
| Massimo di 52 settimane | ₹220.36 |
| Minimo di 52 settimane | ₹132.30 |
| Beta | 0.32 |
| Variazione di 1 mese | 20.65% |
| Variazione a 3 mesi | 21.66% |
| Variazione di 1 anno | 10.85% |
| Variazione a 3 anni | 114.96% |
| Variazione a 5 anni | n/a |
| Variazione dall'IPO | 12.46% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Aug 19
PPLPHARMA: New Turbhe Facility And Board Meeting Will Shape Outlook
Analysts have lifted their price target on Piramal Pharma from ₹170 to ₹200, citing updated assumptions for slightly higher revenue growth, a marginally lower discount rate, a revised profit margin profile, and a higher future P/E multiple. What’s in the News for Piramal Pharma Piramal Pharma Solutions launched a spray drying suite at its peptide development and manufacturing facility in Turbhe, India, to handle complex formulations for peptides and other complex molecules.
Aggiornamento narrativa • Aug 05
PPLPHARMA: Future Upside Will Stem From CDMO Wins And Margin Expansion
Analysts have raised their fair value price target for Piramal Pharma from about ₹203 to roughly ₹233, citing updated assumptions that reflect revised views on revenue growth, profit margins and future P/E levels. What’s in the News for Piramal Pharma Piramal Pharma has scheduled a board meeting on Jul 29, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.Articolo di analisi • Aug 03
Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported And Analysts Have Been Lifting Their Price Targets
As you might know, Piramal Pharma Limited ( NSE:PPLPHARMA ) just kicked off its latest first-quarter results with some...Recent updates
Aggiornamento narrativa • Aug 19
PPLPHARMA: New Turbhe Facility And Board Meeting Will Shape Outlook
Analysts have lifted their price target on Piramal Pharma from ₹170 to ₹200, citing updated assumptions for slightly higher revenue growth, a marginally lower discount rate, a revised profit margin profile, and a higher future P/E multiple. What’s in the News for Piramal Pharma Piramal Pharma Solutions launched a spray drying suite at its peptide development and manufacturing facility in Turbhe, India, to handle complex formulations for peptides and other complex molecules.Aggiornamento narrativa • Aug 05
PPLPHARMA: Future Upside Will Stem From CDMO Wins And Margin Expansion
Analysts have raised their fair value price target for Piramal Pharma from about ₹203 to roughly ₹233, citing updated assumptions that reflect revised views on revenue growth, profit margins and future P/E levels. What’s in the News for Piramal Pharma Piramal Pharma has scheduled a board meeting on Jul 29, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended Jun 30, 2026.Articolo di analisi • Aug 03
Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported And Analysts Have Been Lifting Their Price Targets
As you might know, Piramal Pharma Limited ( NSE:PPLPHARMA ) just kicked off its latest first-quarter results with some...Aggiornamento narrativa • Jul 22
PPLPHARMA: Board Results And New Supply Deal Will Shape Outlook
Analysts have revised their fair value estimate for Piramal Pharma to ₹170 from ₹195. This reflects updated assumptions on discount rate, revenue growth, profit margins and future P/E expectations.
Aggiornamento narrativa • Jul 08
PPLPHARMA: Dual-Site Supply Expansion Will Support Stronger Long-Term Upside Potential
Analysts have adjusted their fair value estimate for Piramal Pharma to ₹255 from ₹310, reflecting updated assumptions on revenue growth, profit margins, and future P/E expectations. What's in the News Piramal Pharma Solutions entered a manufacturing and supply arrangement with Botanix SB Inc.Aggiornamento narrativa • Jun 24
PPLPHARMA: Future Upside Will Stem From Stable CDMO Pipeline Execution
Analysts have kept their price target for Piramal Pharma broadly unchanged at ₹203. This reflects stable assumptions on fair value, discount rate, revenue growth, profit margin and future P/E in their latest update.Aggiornamento narrativa • Jun 05
PPLPHARMA: Future Upside Will Stem From ADC Manufacturing And CDMO Milestones
The analyst price target for Piramal Pharma is unchanged at ₹203, as analysts consider their existing assumptions on revenue growth, profit margins and forward P/E to remain appropriate for the stock at this stage. What's in the News Piramal Pharma Solutions entered a manufacturing and supply arrangement with Botanix SB Inc.Aggiornamento narrativa • May 20
PPLPHARMA: Future Upside Will Stem From ADC And CDMO Milestones
Analysts have nudged their fair value estimate for Piramal Pharma to ₹203.0 per share, up from ₹200.1, reflecting updated assumptions for revenue growth, profit margins, and a higher future P/E multiple. What's in the News Piramal Pharma Solutions entered a manufacturing and supply arrangement with Botanix SB Inc.Aggiornamento narrativa • Apr 24
PPLPHARMA: Future Upside Will Stem From ADC Milestones And Portfolio Expansion
Analysts have kept their Piramal Pharma fair value estimate unchanged at ₹200.10. This reflects broadly steady assumptions on growth, margins and future P/E that together keep the price target in line with prior views.Aggiornamento narrativa • Apr 09
PPLPHARMA: Future Upside Will Stem From ADC Platform And Portfolio Expansion
Analysts have trimmed their price target for Piramal Pharma from ₹204.60 to ₹200.10, citing updates to long term assumptions on revenue growth and profit margins, as well as a slightly lower future P/E multiple. What's in the News Piramal Pharma Solutions completed its 1,500th antibody drug conjugate batch at its Grangemouth, UK bioconjugate facility.Aggiornamento narrativa • Mar 26
PPLPHARMA: Future Upside Will Stem From Acquisitions And Portfolio Expansion
Narrative update on Piramal Pharma price target The analyst fair value estimate for Piramal Pharma is maintained at ₹204.6 per share, with analysts citing unchanged assumptions on discount rate, revenue growth, profit margin and future P/E to support keeping the target steady. What's in the News Piramal Pharma Solutions completed its 1,500th antibody drug conjugate batch at the Grangemouth, UK bioconjugate development and manufacturing site, marking a commercial oncology ADC batch and underlining the facility's role in proof of concept, clinical, and commercial-scale production (Key Developments).Aggiornamento narrativa • Mar 11
PPLPHARMA: Future Upside Will Stem From Acquisitions And Portfolio Expansion
Analysts have kept their fair value estimate for Piramal Pharma steady at ₹204.6 per share, citing unchanged assumptions for discount rate, revenue growth, profit margin and future P/E, and so the overall analyst price target remains effectively unchanged. What's in the News Piramal Pharma plans to keep pursuing acquisitions, along with co development and licensing, to add products to its portfolio as part of its overall growth plan, according to Global Pharma CEO Peter DeYoung (Key Developments).Aggiornamento narrativa • Feb 25
PPLPHARMA: Future Upside Will Stem From Portfolio Expansion And Compliance Progress
Analysts have kept Piramal Pharma's fair value estimate steady at ₹204.6 while trimming the assumed future P/E multiple from 36.72x to 29.82x, reflecting a more conservative view on how much investors may eventually be willing to pay for its earnings. What's in the News Piramal Pharma plans to look for acquisitions, with CEO Peter DeYoung highlighting co-development, licensing, and acquisitions as key ways to add to the portfolio alongside growth in the existing base business, including the inhalation portfolio outside the U.S. as more markets are registered from the Digwal facility (Key Developments).Aggiornamento narrativa • Feb 09
PPLPHARMA: Future Upside Will Stem From Inhalation Portfolio And Compliance Progress
Analysts have trimmed their fair value estimate for Piramal Pharma from ₹234.9 to ₹204.6, citing updated assumptions that reflect slightly more conservative revenue growth and P/E expectations, along with a modest adjustment in the discount rate and profit margin outlook. What's in the News Piramal Pharma plans to pursue acquisitions, co development and licensing opportunities to add to its portfolio, alongside efforts to grow its existing base business.Articolo di analisi • Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Reported Earnings, And Analysts Cut Their Target Price
Piramal Pharma Limited ( NSE:PPLPHARMA ) just released its latest quarterly report and things are not looking great. It...Aggiornamento narrativa • Jan 24
PPLPHARMA: Future Upside Will Stem From ADC Collaboration Progress
Analysts have trimmed their fair value estimate for Piramal Pharma to ₹234.90 from ₹239.90, reflecting slightly softer assumptions on revenue growth, profit margins and the future P/E multiple. What's in the News Piramal Pharma has scheduled a board meeting on January 28, 2026 to consider and approve its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Articolo di analisi • Jan 15
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Aggiornamento narrativa • Jan 08
PPLPHARMA: Future Upside Will Stem From ADC Collaboration Momentum
Analysts have lowered their fair value estimate for Piramal Pharma from ₹244.33 to ₹239.90, citing updated assumptions around revenue growth, profit margin and future P/E expectations. What's in the News Piramal Pharma Limited has scheduled a Special or Extraordinary Shareholders Meeting via postal ballot in India on January 16, 2026.Aggiornamento narrativa • Dec 21
PPLPHARMA: Future Upside Will Stem From ADC Development Momentum
Analysts have modestly adjusted their price target for Piramal Pharma to ₹244.33 per share, reflecting steady assumptions on growth, margins, and valuation multiples, while maintaining confidence in the company’s long term earnings trajectory. What's in the News Piramal Pharma Solutions has completed its transition to full compliance with evolving global nitrosamine impurity requirements, investing in in house and external testing capabilities to help ensure product safety and regulatory alignment (Key Developments).Aggiornamento narrativa • Dec 07
PPLPHARMA: Medium Term Execution Will Drive Upside From ADC Collaboration
Analysts have modestly revised their price target for Piramal Pharma to Rs 244.33, reflecting unchanged assumptions on discount rate, revenue growth, profit margin, and future valuation multiples, while incorporating incremental confidence in the company’s medium term execution. What's in the News Piramal Pharma Solutions has completed its global nitrosamine compliance program, with all existing commercial products now meeting regulatory standards and enhanced in house and external testing capabilities in place (Key Developments).Aggiornamento narrativa • Nov 23
PPLPHARMA: Collaboration Momentum Will Drive Broader Opportunities in the Coming Year
Analysts have maintained their price target for Piramal Pharma at ₹244.33. They cite modest upward revisions to revenue growth estimates, which are offset by a slight decrease in projected profit margins and a higher future price-to-earnings ratio.Aggiornamento narrativa • Nov 08
PPLPHARMA: New Partnerships Will Drive Future Sector Expansion
Analysts have revised Piramal Pharma's fair value estimate down from ₹258.67 to ₹244.33 per share. This change reflects updated assumptions about revenue growth and profit margins.Articolo di analisi • Nov 06
The Price Is Right For Piramal Pharma Limited (NSE:PPLPHARMA)
With a median price-to-sales (or "P/S") ratio of close to 2.6x in the Pharmaceuticals industry in India, you could be...Articolo di analisi • Sep 10
A Look At The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Piramal Pharma's estimated fair value is ₹173 based on 2 Stage Free Cash Flow to Equity With ₹198 share...Articolo di analisi • Jul 09
Why Investors Shouldn't Be Surprised By Piramal Pharma Limited's (NSE:PPLPHARMA) P/S
There wouldn't be many who think Piramal Pharma Limited's ( NSE:PPLPHARMA ) price-to-sales (or "P/S") ratio of 2.9x is...Articolo di analisi • Jun 13
Piramal Pharma (NSE:PPLPHARMA) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • May 17
Piramal Pharma Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Piramal Pharma Limited ( NSE:PPLPHARMA ) came out with its annual results last week, and we wanted to see how the...Articolo di analisi • Mar 08
Piramal Pharma Limited (NSE:PPLPHARMA) Investors Are Less Pessimistic Than Expected
When close to half the companies in the Pharmaceuticals industry in India have price-to-sales ratios (or "P/S") below...Articolo di analisi • Jan 31
Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Last week, you might have seen that Piramal Pharma Limited ( NSE:PPLPHARMA ) released its quarterly result to the...
Nuova narrativa • Dec 19
CDMO Innovations And Lexington Facility Expansion Will Catalyze Market Growth And Boost Earnings
Strategic investments in facility expansion and hospital generics, along with cost optimization, aim to drive growth and sustain healthy EBITDA margins.Articolo di analisi • Oct 26
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
It's been a good week for Piramal Pharma Limited ( NSE:PPLPHARMA ) shareholders, because the company has just released...Articolo di analisi • Oct 25
Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Articolo di analisi • Jul 14
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Articolo di analisi • Jun 17
Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Piramal Pharma's estimated fair value is ₹133 based on 2 Stage Free Cash Flow to Equity Piramal Pharma's...Articolo di analisi • May 21
We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
Piramal Pharma Limited's ( NSE:PPLPHARMA ) stock was strong after they recently reported robust earnings. We did some...Articolo di analisi • Mar 26
It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
With a median price-to-sales (or "P/S") ratio of close to 2.3x in the Pharmaceuticals industry in India, you could be...Articolo di analisi • Feb 28
Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Piramal Pharma fair value estimate is ₹141 Piramal Pharma's...Articolo di analisi • Feb 02
Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Last week, you might have seen that Piramal Pharma Limited ( NSE:PPLPHARMA ) released its quarterly result to the...Articolo di analisi • Nov 09
Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights The projected fair value for Piramal Pharma is ₹144 based on 2 Stage Free Cash Flow to Equity Piramal...Articolo di analisi • Aug 11
Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Piramal Pharma fair value estimate is ₹123 Current share price...Rendimenti per gli azionisti
| PPLPHARMA | IN Pharmaceuticals | IN Mercato | |
|---|---|---|---|
| 7D | 3.4% | -0.3% | -0.2% |
| 1Y | 10.9% | 14.6% | 2.4% |
Ritorno vs Industria: PPLPHARMA ha avuto una performance inferiore rispetto al Indian Pharmaceuticals che ha registrato un rendimento 14.6 % nell'ultimo anno.
Rendimento vs Mercato: PPLPHARMA ha superato il mercato Indian che ha restituito 2.4 % nell'ultimo anno.
Volatilità dei prezzi
| PPLPHARMA volatility | |
|---|---|
| PPLPHARMA Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Prezzo delle azioni stabile: PPLPHARMA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Indian.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di PPLPHARMA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2020 | 7,120 | n/a | www.piramalpharma.com |
Piramal Pharma Limited opera come azienda farmaceutica in Nord America, Europa, Giappone, India e a livello internazionale. L'azienda offre un portafoglio di prodotti e servizi farmaceutici attraverso strutture di sviluppo e produzione globali e una rete di distribuzione. Gestisce inoltre un'organizzazione di sviluppo e produzione a contratto che fornisce servizi in tutto il ciclo di vita del farmaco, tra cui la scoperta, lo sviluppo e la produzione commerciale di sostanze e prodotti farmaceutici; un'attività di generici ospedalieri complessi che offre anestetici per inalazione, terapia intratecale per la gestione della spasticità, farmaci iniettabili per il dolore e l'anestesia e altri prodotti generici e speciali; e un'attività di assistenza sanitaria al consumo in India che comprende analgesici, cura della pelle, integratori vitaminici/minerali, benessere dei bambini, digestivi, salute delle donne, igiene e protezione.
Piramal Pharma Limited Riepilogo dei fondamenti
| PPLPHARMA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | ₹283.58b |
| Utili (TTM) | -₹3.14b |
| Ricavi(TTM) | ₹92.05b |
3.1x
Rapporto P/S-90.4x
Rapporto P/EPPLPHARMA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| PPLPHARMA Conto economico (TTM) | |
|---|---|
| Ricavi | ₹92.05b |
| Costo del fatturato | ₹37.36b |
| Profitto lordo | ₹54.69b |
| Altre spese | ₹57.83b |
| Utili | -₹3.14b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -2.36 |
| Margine lordo | 59.41% |
| Margine di profitto netto | -3.41% |
| Rapporto debito/patrimonio netto | 70.0% |
Come si è comportato PPLPHARMA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/21 16:19 |
| Prezzo dell'azione a fine giornata | 2026/08/21 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2026/03/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Piramal Pharma Limited è coperta da 18 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Harith Ahamed | Avendus Spark |
| Vijayaraghavan Swaminathan | Avendus Spark |